CL2013001137A1 - Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad - Google Patents

Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad

Info

Publication number: CL2013001137A1
Authority: CL; Chile
Prior art keywords: difluoropiperidin; froma; oxobutyl; pyrido; pyrimidin
Prior art date: 2010-11-01

Application number

CL2013001137A

Other languages

English (en)

Inventor

Bong Chan Kim

Kyu Young Kim

Ki Sook Park

Jung Min Yun

Ji Hye Lee

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-01

Filing date

2013-04-25

Publication date

2013-09-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45995015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-25 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2013-09-06 Publication of CL2013001137A1 publication Critical patent/CL2013001137A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL2013001137A 2010-11-01 2013-04-25 Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad CL2013001137A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR20100107868		2010-11-01

Publications (1)

Publication Number	Publication Date
CL2013001137A1 true CL2013001137A1 (es)	2013-09-06

Family

ID=45995015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001137A CL2013001137A1 (es)	2010-11-01	2013-04-25	Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad

Country Status (29)

Country	Link
US (1)	US8859567B2 (es)
EP (1)	EP2635580B1 (es)
JP (1)	JP6193762B2 (es)
KR (1)	KR101446789B1 (es)
CN (1)	CN103189375B (es)
AP (1)	AP3287A (es)
AR (1)	AR083591A1 (es)
AU (1)	AU2011324253B2 (es)
BR (1)	BR112013010586A2 (es)
CA (1)	CA2814357C (es)
CL (1)	CL2013001137A1 (es)
CO (1)	CO6710945A2 (es)
DO (1)	DOP2013000090A (es)
EA (1)	EA024679B1 (es)
EC (1)	ECSP13012599A (es)
GE (1)	GEP20156218B (es)
IL (1)	IL225808A (es)
MA (1)	MA34625B1 (es)
MX (1)	MX341584B (es)
MY (1)	MY156428A (es)
NZ (1)	NZ609644A (es)
PE (3)	PE20140392A1 (es)
PH (1)	PH12013500685A1 (es)
SG (1)	SG189931A1 (es)
TW (1)	TWI519533B (es)
UA (1)	UA106445C2 (es)
UY (1)	UY33696A (es)
WO (1)	WO2012060590A2 (es)
ZA (1)	ZA201302646B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5066175B2 (ja)	2006-03-31	2012-11-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
US9371311B2 (en)	2008-06-30	2016-06-21	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine derivatives
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA201591648A1 (ru)	2013-03-06	2016-02-29	Янссен Фармацевтика Нв	Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
PE20231943A1 (es) *	2020-10-13	2023-12-05	Lg Chemical Ltd	Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma
KR20250137744A (ko)	2024-03-11	2025-09-19	엠에프씨 주식회사	제미글립틴의 신규 결정형 및 이의 제조방법
KR20250147756A (ko)	2024-03-27	2025-10-14	엠에프씨 주식회사	신규한 형태의 제미글립틴 말산염 결정형 및 이의 제조방법
KR20250155700A (ko)	2024-04-24	2025-10-31	주식회사 다산제약	제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물
CN119285630B (zh) *	2024-09-05	2025-05-27	安徽峆一药业股份有限公司	一种吉格列汀草酸盐及其晶型、制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004007468A1 (en) *	2002-07-15	2004-01-22	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
EP1592689A4 (en) *	2003-01-31	2008-12-24	Merck & Co Inc	3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TWI357902B (en)	2005-04-01	2012-02-11	Lg Life Science Ltd	Dipeptidyl peptidase-iv inhibiting compounds, meth

2011
- 2011-10-27 TW TW100139075A patent/TWI519533B/zh active
- 2011-10-28 KR KR1020110111672A patent/KR101446789B1/ko active Active
- 2011-10-28 AR ARP110103993A patent/AR083591A1/es unknown
- 2011-10-28 UY UY0001033696A patent/UY33696A/es unknown
- 2011-10-31 PE PE2013000904A patent/PE20140392A1/es not_active Application Discontinuation
- 2011-10-31 NZ NZ609644A patent/NZ609644A/en active IP Right Revival
- 2011-10-31 CA CA2814357A patent/CA2814357C/en active Active
- 2011-10-31 UA UAA201305462A patent/UA106445C2/ru unknown
- 2011-10-31 EA EA201390644A patent/EA024679B1/ru unknown
- 2011-10-31 MA MA35861A patent/MA34625B1/fr unknown
- 2011-10-31 PE PE2023001454A patent/PE20240220A1/es unknown
- 2011-10-31 SG SG2013029434A patent/SG189931A1/en unknown
- 2011-10-31 PH PH1/2013/500685A patent/PH12013500685A1/en unknown
- 2011-10-31 EP EP11838195.3A patent/EP2635580B1/en not_active Revoked
- 2011-10-31 AP AP2013006866A patent/AP3287A/xx active
- 2011-10-31 WO PCT/KR2011/008186 patent/WO2012060590A2/en not_active Ceased
- 2011-10-31 MX MX2013004776A patent/MX341584B/es active IP Right Grant
- 2011-10-31 JP JP2013536534A patent/JP6193762B2/ja active Active
- 2011-10-31 PE PE2018000088A patent/PE20180464A1/es unknown
- 2011-10-31 GE GEAP201113077A patent/GEP20156218B/en unknown
- 2011-10-31 CN CN201180052217.1A patent/CN103189375B/zh active Active
- 2011-10-31 US US13/879,571 patent/US8859567B2/en active Active
- 2011-10-31 MY MYPI2013001318A patent/MY156428A/en unknown
- 2011-10-31 BR BR112013010586A patent/BR112013010586A2/pt not_active Application Discontinuation
- 2011-10-31 AU AU2011324253A patent/AU2011324253B2/en active Active
2013
- 2013-04-11 ZA ZA2013/02646A patent/ZA201302646B/en unknown
- 2013-04-17 IL IL225808A patent/IL225808A/en active IP Right Grant
- 2013-04-22 DO DO2013000090A patent/DOP2013000090A/es unknown
- 2013-04-25 CL CL2013001137A patent/CL2013001137A1/es unknown
- 2013-04-30 CO CO13108961A patent/CO6710945A2/es unknown
- 2013-05-02 EC ECSP13012599 patent/ECSP13012599A/es unknown

Also Published As

Publication number	Publication date
JP2013540810A (ja)	2013-11-07
WO2012060590A3 (en)	2012-06-28
MA34625B1 (fr)	2013-10-02
MX2013004776A (es)	2013-11-04
EP2635580A2 (en)	2013-09-11
CA2814357C (en)	2015-07-07
AP2013006866A0 (en)	2013-05-31
US8859567B2 (en)	2014-10-14
AU2011324253B2 (en)	2015-10-29
PE20140392A1 (es)	2014-03-22
UA106445C2 (ru)	2014-08-26
MX341584B (es)	2016-08-25
CA2814357A1 (en)	2012-05-10
US20130203787A1 (en)	2013-08-08
PH12013500685A1 (en)	2015-10-02
BR112013010586A2 (pt)	2016-08-09
AP3287A (en)	2015-05-31
ECSP13012599A (es)	2013-07-31
AR083591A1 (es)	2013-03-06
AU2011324253A1 (en)	2013-05-02
KR20120046069A (ko)	2012-05-09
WO2012060590A2 (en)	2012-05-10
EP2635580B1 (en)	2015-08-12
GEP20156218B (en)	2015-01-12
EP2635580A4 (en)	2014-04-02
TWI519533B (zh)	2016-02-01
SG189931A1 (en)	2013-06-28
IL225808A0 (en)	2013-06-27
NZ609644A (en)	2016-02-26
TW201245189A (en)	2012-11-16
UY33696A (es)	2012-04-30
KR101446789B1 (ko)	2014-10-01
CN103189375A (zh)	2013-07-03
CN103189375B (zh)	2016-08-10
EA201390644A1 (ru)	2014-11-28
IL225808A (en)	2016-08-31
PE20180464A1 (es)	2018-03-06
MY156428A (en)	2016-02-26
ZA201302646B (en)	2014-01-29
JP6193762B2 (ja)	2017-09-06
PE20240220A1 (es)	2024-02-16
EA024679B1 (ru)	2016-10-31
DOP2013000090A (es)	2018-06-30
CO6710945A2 (es)	2013-07-15

Similar Documents

Publication	Publication Date	Title
CL2013001137A1 (es)	2013-09-06	Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad
CL2014000343A1 (es)	2014-10-17	Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
ZA201700035B (en)	2020-05-27	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2013003051A1 (es)	2014-07-11	Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2009000447A1 (es)	2010-01-04	Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
BRPI0817028A2 (pt)	2019-09-24	composto inibidor de diacilglicerol acil tranferase, composição farmacêutica que o contém, uso do composto, métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação e dislidemias e diabetes do tipo ii
CL2012000163A1 (es)	2012-07-13	Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
CL2015002635A1 (es)	2016-02-19	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2013002341A1 (es)	2014-04-04	Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
BR112012001031A2 (pt)	2016-11-22	compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência.
CL2009000309A1 (es)	2009-06-26	Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2014000849A1 (es)	2014-08-29	Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
IL240949B (en)	2019-05-30	Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
CL2013001565A1 (es)	2014-04-04	Metodo para tratar la ingesta excesiva o comer compulsivamente, que comprende el uso de bupropion y naltrexona y la composicion farmaceutica que comprende a ambos compuestos.
IL199829A0 (en)	2010-04-15	Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
IL217294A (en)	2015-07-30	History 3,2 - Dihydro - 1h - Imidazo [1, 2 - a] - Pyrimidin - 5 - On, process for their preparation, pharmaceutical preparations containing them and their use in the preparation of medicines
CL2007003643A1 (es)	2008-03-24	Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
DK2149372T3 (da)	2014-07-07	Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
CL2014000493A1 (es)	2014-10-03	(r)-7-(2-(1-(4-butoxifenil)-2-metilpropan-2-ilamino)-1-hidroxietil)-5-hidroxibenzo[d]tiazol-2(3h)-ona; proceso de preparacion; composicion y combinacion farmaceutica que lo comprende; y uso en el tratamiento y prevencion de la distrofia muscular, atrofia por desuso, caquexia o sarcopenia.
IL214028A (en)	2015-11-30	A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition
AR093327A1 (es)	2015-06-03	Analogos quimericos de somatostatina-dopamina
CL2008000497A1 (es)	2008-08-29	Compuestos derivados de ciclohexil-amida del acido aril-carboxilico, antagonistas del receptor de quimiocina 2 y 5; proceso de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad o con
ES2389424B1 (es)	2013-09-09	Procedimiento para la visualizacion de superficies en el cuerpo humano.